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Abstract
The WHO has ranked environmental hazardous exposures in the living and working environment among the top
risk factors for chronic disease mortality. Worldwide, about 40 million people die each year from noncommunicable
diseases (NCDs) including cancer, diabetes, and chronic cardiovascular, neurological and lung diseases. The exposure to
ambient pollution in the living and working environment is exacerbated by individual susceptibilities and lifestyle-driven
factors to produce complex and complicated NCD etiologies.
Research addressing the links between environmental exposure and disease prevalence is key for prevention of the
pandemic increase in NCD morbidity and mortality. However, the long latency, the chronic course of some diseases and
the necessity to address cumulative exposures over very long periods does mean that it is often difficult to identify
causal environmental exposures.
EU-funded COST Action DiMoPEx is developing new concepts for a better understanding of health-environment
(including gene-environment) interactions in the etiology of NCDs. The overarching idea is to teach and train scientists
and physicians to learn how to include efficient and valid exposure assessments in their research and in their clinical
practice in current and future cooperative projects.
DiMoPEx partners have identified some of the emerging research needs, which include the lack of evidence-based
exposure data and the need for human-equivalent animal models mirroring human lifespan and low-dose cumulative
exposures. Utilizing an interdisciplinary approach incorporating seven working groups, DiMoPEx will focus on aspects of
air pollution with particulate matter including dust and fibers and on exposure to low doses of solvents and sensitizing
agents. Biomarkers of early exposure and their associated effects as indicators of disease-derived information will be
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tested and standardized within individual projects. Risks arising from some NCDs, like pneumoconioses, cancers and
allergies, are predictable and preventable. Consequently, preventative action could lead to decreasing disease morbidity
and mortality for many of the NCDs that are of major public concern. DiMoPEx plans to catalyze and stimulate
interaction of scientists with policy-makers in attacking these exposure-related diseases.
Keywords: Noncommunicable diseases, Human biomonitoring, Environmental/occupational exposure to xenobiotics
Background
Adverse health outcomes because of exposure received in
the living and working environments in combination with
lifestyle have been estimated to be responsible for up to
75% of global noncommunicable diseases (NCDs) [1, 2].
Chronic diseases resulting from these exposures provide a
major contribution not only to the NCD burden but also
to the resulting increase in health costs. Since most of
these diseases are preventable, appropriate health policies
should concentrate on this major societal challenge.
In 2010, about 40 million people died worldwide from
NCDs, including cancer, diabetes, and chronic cardio-
vascular, neurological and lung diseases [3]. This repre-
sents an increase from 60% of total deaths attributed to
these diseases in the year 2000 to 70% (total deaths)
within 10 years (see Additional file 1: Info Box 1, for
more details). In 2015, the World Health Organization
(WHO) ranked environmental exposures among the top
risk factors for chronic disease mortality [4]. Pollution
(from air, soil, water) is one of the leading causes of
death from NCDs (for other environmental factors see
Table 1). Worldwide, diseases related to environmental
pollution were responsible for 9 million premature
deaths in 2015 - three times as many deaths as from
AIDS, tuberculosis and malaria combined [5]. Every year,
environmental risks – such as indoor and outdoor air
pollution, second-hand smoke, unsafe water, lack of
sanitation and inadequate hygiene – take the lives of 1.7
million children under 5 years, reported WHO in 2017
[6]. Ambient air pollution alone is estimated to cause
7 million premature deaths per year (recently highlighted
in the Global Burden of Disease (GBD project [7]). Data
from the GBD study group demonstrate a strong link
between both indoor and outdoor air pollution exposure
and cardiovascular disease (CVD), as well as between air
pollution and cancer [8]. In some parts of the European
Union (EU), air pollution causes a reduction in the aver-
age life expectancy of more than one year [9, 10].
The concept of the “exposome” as the total of all
external exposures, along with individual susceptibility
due to genetic, age-related, and other vulnerabilities, is
gaining increasing credence from both the scientific and
clinical communities [11, 12]. Pollutants, food additives,
chemicals found in cosmetic products and therapeutic
exposure (chemo−/ radio therapy) are prime examples
of such cumulative exposures. Certain pesticides, such
as organophosphates, are examples of man-made chemi-
cals to which large populations in agricultural communi-
ties are exposed, as well as consumers via their diet, and
contribute to neurotoxicity in human populations
worldwide [13–15]. The compromising of health (effect
Table 1 Synopsis
The main purpose of the European Cooperation in Science and Technology
program is to provide a framework for international cooperation among
researchers and other professionals. By bringing together experts in
significant areas of human life and development, opens up the possibilities
of new ideas, approaches and solutions. The European Cooperation in
Science and Technology COST program is founded partially by the member
states, who delegate the management committee members. The Action
Diagnosis, Monitoring and Prevention of Exposure-related Noncommunicable
Diseases (DiMoPEx) fosters capacity-building by bringing together basic
scientists, clinical researchers and practitioners in the relevant (sub-)disciplines
and organizing interdisciplinary collaboration and training in research that
addresses the societal challenges outlined above. Members aim to
implement new concepts in joint interdisciplinary research and training
initiatives to enhance networking between expert centers and offer a
platform for interdisciplinary collaboration between researchers across
Europe. DiMoPEx also aims to attract and focus the interests of the next
generation of early career investigators on key emerging issues of
exposure-related disease burden and various aspects of exposure
assessment sciences.
The predominant goal is to help scientists, physicians and health officials
to prevent and reduce health impacts associated with various exposure
scenarios and train highly skilled researchers of health-environment
(including gene-environment) interactions in the etiology of
exposure- related NCDs within seven working groups
The overarching idea of the DiMoPEx project (http://dimopex.eu/
working) groups is to teach and train about how to learn to include
evidence-based exposure assessment (in research and clinical settings).
Using modern methods such as ambient monitoring and human
biomonitoring methods (WG1, WG 2), the various biomarkers of effect
and susceptibility alongside with the clinical diagnostic methods and
biomarker-based evaluation of lifestyle factors (WG3, WG 6) can be
combined, resulting in the development of cooperative projects that are
too broad for coverage by individual disciplines (i.e. epidemiology or
traditional environmental medicine). Within several joint research
projects, DiMoPEx partners are already focusing on the impact of
pollution on human health. The projects are concentrating on several
pollutants (particulate mass fractions PM2.5 and PM10, a range of metals,
inorganic gases and organic compounds) in living and working
environments and their health impacts [138].
The DiMoPEx Action anticipates initiating health research with important
benefits for public health and the healthcare system of the European
Community. DiMoPEx will catalyze and stimulate interaction of scientists
with policy-makers on exposure-related diseases of concern to society
(see below, WG 7 for more details on cooperation with the WHO scientists,
implementation of the new knowledge, involving external partners and
policy makers). See below for detailed working groups description.
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measure modifications, EMM) is possible through life-
style factors such as smoking, alcohol abuse and bad
nutrition/obesity, as well as through interactions
between these. For example, smoking increases the risk
of lung cancer (through co-exposure to asbestos, radon
or arsenic) from < 20% (exposure alone) to over 80% ex-
cess risk because of the synergistic effects [16]. Health
hazards also arise from the globalization of trade [17]
and production processes with direct and indirect envir-
onmental and occupational health impacts [18, 19]. Fur-
ther, new hazards are continuously being discovered,
such as those related to the introduction of nanopro-
ducts in industrial and consumer goods [20].
The long latency periods, combined cumulative expo-
sures and chronic course of diseases often makes it diffi-
cult to identify environmental/occupational exposure as
the cause of NCDs [21, 22]. One source of exposure may
cause several outcomes and also different types of expos-
ure may affect the same disease outcome; for example, air
pollution has been linked to a number of common
diseases, including cardiovascular, cerebrovascular, re-
spiratory, reproductive, neuro-developmental and neuro-
degenerative diseases. [23] Conversely, multiple exposures
may have a cumulative effect on the same target organ.
At the patho-physiological level, exposure-related
NCDs arise as a result of interactions between internal
(genetic, epigenetic, hormonal, aging etc.) factors and
external (occupational/environmental) influences [24].
In recent years, enormous progress in the exploration of
genetic and epigenetic factors and resulting disease risks
has been made. This knowledge has already found its
way into the contents of academic teaching programs in
medical schools and postgraduate courses (e.g. in
molecular epidemiology, neurosciences, personalized
medicine). In contrast, the other major and modifiable
dimension of pathogenesis, the influence of occupa-
tional/environmental exposure and lifestyle factors, has
received comparatively little attention. Current figures
published by WHO (see Additional file 1: Info Box 1) in-
dicate an urgent need for an update in the research and
training potential concerning environmental health is-
sues, and in implementing public health research across
Europe, with an interdisciplinary evidence-based orienta-
tion in the natural sciences, public health and medicine.
Outline
This review assesses the current status and future needs
of the multicenter European COST Action DiMoPEx
(http://www.cost.eu/COST_Actions/ca/CA15129). The sep-
arate sections represent the identified current research ob-
jectives and future goals of the DiMoPEx action. It reflects
the structure of this multicenter action with 7 working
groups (http://dimopex.eu/working), highlighting the role
of individual working groups within the DiMoPEx
framework and the specific methods provided by individ-
uals groups for the ongoing and planned collaborative
projects. A short description of the ongoing interdisciplin-
ary research projects is also provided demonstrating how
the evidence-based exposure data can be applied for the
diagnosis and monitoring of exposure-related NCDs (from
the perspective of the action partner).
DiMoPEx project goals identified by the project
partners
How to improve diagnosis, monitoring and prevention of
NCDs?
Current status and future needs to be addressed
DiMoPEx partners recognize an important research
need: to link the living and working environment with
disease prevalence in order to prevent the pandemic in-
crease in NCD morbidity and mortality. Public health
benefits may range from effective preventative measures
to early detection of possible adverse health outcomes.
Four of the currently identified emerging research tasks
pursued by DiMoPEx include the following:
1. To face the difficulties in NCD diagnosis and
monitoring of disease progress
Many ongoing long-term studies focusing on early
signs of related chronic diseases account insufficiently
for environmental/occupational determinants of
health. Other studies addressing health outcomes in
relation to exposures in the living and working
environment do not sufficiently account for existing
knowledge regarding appropriate exposure measures
in their study designs (i.e. some record ever/never
occupational exposure or self-reporting of specific
chemicals, leading to exposure misclassification and
biased results). The effects of multiple exposures and
EMM within the same target organ should also be
addressed. It is time now to take a closer look at the
living and working environment and focus on
evidence-based exposure data that has the potential to
correlate exposure with disease, which otherwise
provides an obstacle to evidence-based
recommendations for primary and secondary
NCD prevention.
2. To focus on biomarkers of early response and
appropriate human-equivalent animal models
(carcinogenicity bioassays to provide a basis for
evidence- based interventions
Evidence-based interventions have already
successfully limited exposure to many known and
probable carcinogens, including tobacco, arsenic,
asbestos, benzene, vinyl chloride and air pollution.
However, among NCDs, cancer is still the second
leading cause of death: in 2014 about 591,699 of
people died from cancer in the United States alone
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[25]. Cancer is an extremely complex disease, not
easy to control, and one about which there is
insufficient knowledge in terms of etiology. To
provide a solid scientific basis for cancer prevention,
it is necessary to increase our knowledge about
cancer etiology. Basic as well as preventative and
clinical research should be developed. In this
research, well-designed experimental animal studies
[26] and biomarkers of early response should play a
central role (carcinogenicity bioassays).
3. To focus on air pollution as one of the major
factors responsible for NCD mortality
There is a strong link between both indoor and
outdoor air pollution exposure and CVD, as well as
between air pollution and cancer. Knowledge of
what it is that makes a particle toxic may provide
better exposure metrics in epidemiology studies, lead
to more efficient abatement strategies to reduce
emissions of the most hazardous air pollutants and
allow for production of nanoparticles that can be
shown to be benign. Being able to predict the
toxicity of particulates based on knowledge of size,
composition and material properties would also be a
prerequisite for reducing the need for extensive
toxicity testing of new nano-materials. The oxidative
potential of particles is considered by many to be a
promising metric to predict particle toxicity.
4. To recognize the need for the public-health
protection through cooperation with
policy-makers
To benefit societies and enhance the wellbeing of
populations and decrease morbidity and mortality
from exposure-related NCDs, there is a need for
innovation in public health and environment policy
and in the business practices of certain industries,
leading to healthier environments, as well as a better
understanding of risk communication, including its
ethical aspects. There is a need to catalyze and
stimulate interaction between scientists and
policy-makers in respect of exposure-related diseases
of concern to society. The predominant goal should
be to help scientists, physicians and health officials to
prevent and reduce health impacts associated with
various exposure scenarios and to train highly skilled
researchers for the future labor market.
Implementation of the research goals within the
framework of the 7 WGs
The identification of a xenobiotic chemical and the
documentation of the degree and extent of exposure by
the WG 1 project is fundamental to the investigation of
the disruptive effects of that exposure and its conse-
quences for NCDs, which are the specialist interests of
the WG 5, WG 2 and WG 6 projects in determining the
biohazard consequences in carcinogenicity, genotoxicity
and health effects. WG 3, WG 4 and WG 7 support
other groups with knowledge on epidemiology and/or
risk communication and canvassing meetings with policy
makers to influence environmental/occupational laws,
funding groups, etc.
Detailed descriptions of methods applied, issues to
be concentrated on within the project and further
examples of current activities are summarized in the
following sections.
WG 1 advancing towards evidence-based
exposure data
Exposure assessment – From environmental to individual
exposure
An accurate exposure assessment needs consideration of
a wide spectrum of sources, the different pathways and
routes of exposure, and the environmental and physio-
logical effects of the xenobiotics [27] (Fig. 1).
The most prominent sources of xenobiotic chemical
exposure are emissions from industrial processes and
engine exhausts, emissions from other combustion pro-
cesses, residues from pesticide and biocide applications,
emissions from consumer populations via waste effluents
(solid waste or wastewater), and indoor air emissions
from building materials, consumer products and furni-
ture. People are mainly exposed to this pollution via out-
door and indoor air, tap water and contaminated food,
as well as direct skin contact with contaminated surfaces
and dermally-applied products, such as cosmetics and
personal care products [28–33]. In some special cases,
exposure may also occur during rainfall, from surface
water, dermal contact or oral ingestion of contaminated
soil, from applications of pesticides, biocides and other
chemical products [34]. Moreover, lifestyle behavior such
as. smoking and the consumption of functional food,
nutriceuticals and the application of pharmaceuticals,
exacerbate the broad spectrum of chemical exposure
experienced by an individual. The manifold emission
sources, polluted materials and exposure scenarios de-
termine that extraneous chemicals gain access to the
body using all possible routes, most especially by inhal-
ation, oral ingestion and via the dermis.
The assessment of chemical exposure has two main
aims. Firstly, the individual pollution agents have to be
clearly identified. Secondly, qualitative detection also
requires ascertainment of the hazards inherent in these
xenobiotics. For risk assessment, however, both the
qualitative character of exposure and the extent of the
exposure have to be estimated. Some approaches of ex-
posure assessment already enable the attainment of both
of these goals, e.g. by a non-target procedure which may
also enable a semi-quantitative determination of the ana-
lytes. However, for those approaches in which specific
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metabolites have to be assessed, the prior identification
of the chemical agent is indispensable before targeted
measurement can be implemented.
A quantitative estimation of exposure can be performed
by a direct or an indirect approach (see Fig. 2). A direct
monitoring approach requires determination of the extent
of exposure of an individual to a chemical by assessment
either externally, internally or as metabolized products.
External measurements of ambient exposure can be made
from air contamination by that chemical or the contamin-
ation of the skin. The internal exposure to a chemical suf-
fered by an individual is by conventional human biological
monitoring and the measurement of the unmodified agent,
as well as its metabolites and reaction products in blood
and urine (see also the later section on human biological
monitoring (WG2)). Inevitably, the levels of internal expos-
ure are most strongly connected with the effective dose
and the subsequent toxic effects [35]. To use data from in-
dividual ambient exposure for risk assessment effectively
then it is necessary for an additional calculation about the
absorption efficiency to be made, e.g. by using minute vol-
ume, respiratory retention or dermal absorption rate.
Indirect approaches of exposure assessment (i.e. dispersion
models or other exposure models, questionnaires on
exposure scenarios, and questionnaires on food intake or
exposure situations) can also be taken as a basis for esti-
mating the levels of environmental contamination. Data
from indirect approaches have to be extrapolated to the
effective dose in the population by considering pollutant
transport processes, accumulation and fate processes in
the environment, exposure scenarios, demographic and
geographic attributes, lifestyle behavior, human constitu-
tion and the pharmacokinetics of the agent. Moreover, an
estimation of individual exposure has to include the intra-
individual variability of these extrapolation factors within
the population [36, 37]. Each extrapolation model should
be validated in respect of its performance and uncertainty.
Regardless of which approach was used for the assessment
of the recent extent of exposure, these might be important
for a reasonable risk assessment and for contemplation of
the duration of exposure [38].
The tasks of the WG1 “Exposure assessment” project
encompass the analysis of skills, expertise and capacities
regarding exposure assessment within the consortium, the
dissemination of resources and information on assessment
procedures and quality assurance, as well as the develop-
ment and expansion of capabilities and capacities. The
most important tasks are the identification of limitations
or crucial gaps in knowledge about exposure quantitiza-
tion and exposure-effect associations, as well as preparing
effective solutions for closure of these knowledge gaps. In
particular, the WG 1 and WG 2 project groups are provid-
ing a sustainable research and training program in the
field of exposure science (human biomonitoring, ambient
monitoring) for the other DiMoPEx partners.
WG 5 hazards characterization, risk identification:
Carcinogenicity bioassays
Diagnosis of cancer as NCD needs biomarker(s) of early
effect (detection of preclinical lesions) and new animal
study approaches
There is a need for human-equivalent animal models
mirroring human lifespan and low dose cumulative
Fig. 1 The wide spectrum of sources needed to ensure accurate exposure assessment
Fig. 2 Quantitative estimation of the exposure performed by a direct
or indirect approach; example from the occupational medicine
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exposures. The laboratory rat has served as the trad-
itional animal model of choice for research and regula-
tory developmental and reproductive toxicity testing
conducted to support human health hazard identifica-
tion and risk assessment. The laboratory rat has been
more thoroughly characterized than have other species
in these research fields, especially when identifying likely
human carcinogens. However, with new insights into
toxicology, novel integrated experimental approaches for
hazard identification are needed with human-equivalent
animal models in rodent bioassays for primary preven-
tion (see Additional file 1: Table S1; [39, 40] and Info
Box 2) for more information on animal models and Or-
ganisation for Economic Co-operation and Development
(OECD) guidelines [41].
When conducting cancer bioassays, it is important to
investigate the effect of low doses and a systematic dose-
calibration study should be performed in an appropriate
rodent model in order to identify the relevant adminis-
tered oral dose of the test substance that results in bio-
marker concentrations (e.g. urine, serum) comparable to
those observed in a human population [42]. Cancer is a
complex disease with diverse etiology; see examples of
exposure related cancer in Additional file 1: Info Box 3,
Table S2 in the supplementary). The neoplastic response
depends not only on the kind of agent, its physicochemi-
cal and toxicological properties, the mode of exposure,
and the type of animal but also, to a great extent, on the
latency of the tumor, which varies widely and may be
very long. Experimental findings indicate that the latent
neoplastic potential for causing a tumor increases with
the length of the observation time or age. Thus, experi-
mental carcinogenicity trials should continue until spon-
taneous animal death and not be cut short. To give a
clearer explanation, one of the the DiMoPEx partners
compared, in preliminary research, human deaths from
malignant tumors at the Hospital of Trieste, in 1989,
with rat deaths from malignant tumors in the RI animal
facility belonging to control groups, in 1984–1994.
Figure 4, which refers to the cumulative prevalence of
animals and humans with malignant tumors, histopatho-
logically observed by age at death, shows that 80% of tu-
mors arise after the age of 65 years in humans, which
corresponds to 104 weeks in rats [43]. According to the
OECD, rats should be sacrificed at 112 weeks of age at
death [43], which corresponded to 104 weeks after the
start of the treatment. If these animals had been sacri-
ficed at 112 weeks of age (comparable to 65 + age in
humans) then the majority of tumors would have been
missed. At the Cesare Maltoni Cancer Research Center
(CMCRC), studies have been conducted on more than
200 compounds present in the industrial and the general
environment, including vinyl chloride, benzene, formal-
dehyde, trichlorethylene, fuels and their components and
additives, pesticides, and recently aspartame, the most
widely diffused artificial sweetener in the world. The re-
sults from the CMCRC studies have provided the scien-
tific basis for lowering exposure levels to various agents
present in places of work and in daily life. They have
also formed the basis for rules and regulations of pri-
mary prevention, even if sometimes many years have
passed before confirmation of their carcinogenicity in
humans (see Additional file 1: Table S3).
Current two-year experimental schemes may mask a
carcinogenic response
Cutting short an experiment after two years may mask a
possible carcinogenic response, as in the following cases
with xylene and mancozeb (see Additional file 1: Table S4)
The increase in total malignant tumors, oral cavity carcin-
omas and hemolymphoreticular neoplasias was only ob-
served for xylene administration after 112 weeks of age
(Fig. 3). It should be noted that during exposure tests for
xylene, performed by the United States National Toxicol-
ogy Program, the rats were sacrificed after 104 weeks of
treatment without any carcinogenic effect being found
[44, 45]. With mancozeb administration, a strong increase
in malignant tumors of the thyroid gland in males and fe-
male rats was also observed after 112 weeks of age [46]. In
demanding that chronic animal studies be terminated
after 2 years, regulatory agencies may lose information
that is important for extrapolation of the data from ani-
mals to humans, most especially for chronic diseases with
a long latency time.
An integrated experimental approach
To satisfy the need to consider multiple effects (e.g.,
cancer and non-cancer) across multiple life stages and to
reduce the overall number of animals required for separ-
ate studies of these end-points, the adaptation of the
carcinogenicity bioassay to integrate additional protocols
for comprehensive long-term toxicity assessment was re-
cently proposed. The central aim of the methodology
proposed in the integrated experimental approach was
to maximize the breadth of outcomes assessed and to in-
crease the sensitivity of testing beyond that in commonly
used protocols. This should yield more reliable and in-
clusive information on many important end-points. In
this experimental design, rats from the same generation
are used for studying chronic toxicity and carcinogen-
icity outcomes and distributed into parallel satellite
experiments for detecting reproductive/developmental
toxicity, thus minimizing variables between different
arms of the multi- end-point investigation [47]. This
protocol is a incentivizing proposal to regulatory scien-
tists and the scientific community in general. By con-
ducting such integrated bioassays, scientific evidence of
risk assessment would be enhanced and expanded, by
Budnik et al. Journal of Occupational Medicine and Toxicology  (2018) 13:6 Page 6 of 22
gathering sufficient and rapid information about several
adverse effects in a unique protocol for protecting
public health.
Biomarker of early response to assess the effects of
preventive measures and identify individuals at high risk
of developing a particular NCD
Efficient patient management relies on early diagnosis of
diseases and monitoring of disease progression. In this
respect, significant efforts have been made to find in-
formative, blood-based biomarkers or liquid biopsy. As
the individual genomic, epigenomic and transcriptomic
profiles of diseases become more and more elucidated,
the applicability of circulating nucleic acids and exo-
somes have the potential to complement the existing
blood biomarkers in future. In addition, the blood-based
detection of disease-specific genetic aberrations, such as
mutations, microsatellite alterations and epigenetic
modulations in circulating free DNA (cfDNA), or quan-
titative changes in cfDNA, RNA, microRNAs (miRNAs)
and exosomes, represent highly promising approaches
for the risk assessment of various diseases. Investigations
of these molecular alterations have also revealed an im-
pact on gene expression, resulting in aberrant regulation
of disease-specific signal transduction pathways. For the
most acute clinical syndromes, it is likely that multiple
markers rather than a single marker will give the best
diagnosis and prognosis.
The use of the cytokinesis-block micronucleus (CBMN)
cytome assay could also be relevant for clinical and epi-
demiological studies and for preventative interventions, be-
cause it could allow the identification of individuals at high
risk of developing a given disease and could even qualify as
an intermediate biomarker to assess the effects of
preventative measures. In prospective studies evaluating
large cohorts of disease-free subjects, an increase in
micronucleus frequency (MN) in peripheral blood lympho-
cytes was associated with an increased cancer risk at the
population level, providing suggestive evidence that this
biomarker may be predictive of cancer risk [48]. Increased
MN frequency was also detected in peripheral lymphocytes
of subjects affected by cancer-associated congenital syn-
dromes characterized by deficiencies in the DNA damage
response [49]. Many studies also showed an increased MN
frequency in peripheral lymphocytes in untreated patients
with cancer or pre-neoplastic lesions [50], neurodegenera-
tive diseases [51], CDV and diabetes [52].
Potential biological effect markers – Circulating nucleic
acids in human blood
Circulating nucleic acids are promising blood-based
biomarkers because of their informative and disease-
specific features. Their deregulated levels are associated
with tumor genesis, tumor progression, metastases and
drug resistance in cancer patients, and reflect physio-
logical and pathological processes of different diseases.
Circulating nucleic acids (in plasma or serum) may serve
as a “liquid biopsy” that is useful for numerous diagnos-
tic and prognostic applications of different (malignant
and benign) diseases, while avoiding tissue biopsies by
invasive methods. This minimally invasive procedure
allows the repeated taking of blood samples, providing
the ability to follow quantitative measurements and gen-
etic or epigenetic changes during the natural course of
the disease, facilitating treatment decisions [53, 54].
Nucleic acids are usually released (Fig. 4) during
cellular stress or tissue injury into the blood circulation.
Their release is associated with inflammatory responses
caused by a coordinated expression of numerous genes
that initiate, sustain and propagate immune responses
and tissue remodelling [55]. This increased cell turnover
and impaired blood clearance are possible reasons for
Fig. 3 New study protocols needed for animal models. Animal models for carcinogenicity bioassays: Hazard identification: carcinogenic effects
may be observed later than 112 weeks after xylene exposure
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the elevated or deregulated levels of circulating nucleic
acids in critical disease conditions where organs respon-
sible for elimination of by-products are damaged (as a
consequence of systemic inflammation). The release of
nucleic acids into the blood circulation occurs during
the processes of apoptosis and necrosis. While apoptotic
cell death leads to controlled inter-nucleosomal cleavage
of genomic DNA, necrotic cell death leads to a discharge
of large genomic DNA fragments [56]. Apart from their
passive release during cell death, nucleic acids can also
be actively excreted into the blood circulation by microve-
sicles, such as exosomes. Exosomes and their cargo are
thought to play an important role in cell-to-cell communi-
cation by influencing the recipient cell phenotype [57].
The concentrations of cfDNA are elevated (as an early
signal) in the blood circulation after onset of disease and
reach the highest level in patients with disease-specific
complications and a high mortality risk. Accordingly, the
elevation in cfDNA levels is not specific for a specific
disease and varies among patients within a patient co-
hort, but may correlate with the severity of disease. Since
cfDNA levels may change during the course of disease
and in parallel with the severity of disorder, they could
provide a useful marker for the assessment of adverse
outcome, allowing clinicians to make a rapid risk stratifi-
cation for more rational therapeutic decisions [58].
Apart from cfDNA, much attention and effort have been
put into the study of cell-free microRNAs (miRNAs) (see
Additional file 1: Table S5, [59–61]). The expression of these
small, non-coding RNA molecules is often tissue-specific
and in many pathological conditions characteristically
deregulated. The clinical relevance of cell-free miRNAs [59]
as diagnostic and prognostic markers has been documented
for a variety of diseases [60]. Besides, miRNAs that are ac-
tively released in exosomes into the blood circulation, can
be transferred to recipient cells [61] and can be functional
there by respressing their mRNA targets [62]. Thus, exo-
somes may serve as suppliers of disease-derived genetic in-
formation and, consequently, transform their host cell as
well. Moreover, exosomal miRNAs stimulate cellular signal-
ling and regulate metabolic functions and homeostasis. The
amounts of secreted exosomes as well as their contents of
miRNAs have been associated with tumor development and
progression, cell migration and proliferation of tumor cells
leading to metastasis [63] . (see Additional file 1: Table S5).
Epigenetic markers in early detection of NCDs
Unlike genetic alterations, which can be stably acquired
during the life-course, epigenetic modifications (see
Additional file 1: Table S6) are dynamic, tissue-specific
and can be characteristic of a disease. In this respect,
epigenetic alterations may be utilized as biomarkers of
exposure and disease and serve as biomolecular sensors
for preventive surveillance [64].
Environmental and occupational factors induce epi-
genetic alterations that can contribute to the onset of
NCDs, of which cancer is one of the most prevalent.
Occupational exposure to chemicals (e.g. benzene), dusts
(e.g. from manufacturing of leather or woods) and/or in-
dustrial processes (welding, metallurgy) can be related to
cancer and the carcinogenic process is linked to changes
in DNA methylation, particularly in its early phases.
Fig. 4 Sources of nucleic acids and NCDs
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Recently, the epigenetic involvement and contribution of
12 chemicals and associated occupations were evaluated
from the literature by the International Agency for
Research on Cancer (IARC). Human carcinogens related
to environmental occupational hazards classified as Group
1 were considered, specifically the three carcinogens afla-
toxin, benzene and benzo[a]pyrene), where several studies
have reported an epigenetic effect [65]. Increasing scien-
tific evidence has linked diseases other than cancer with
epigenetic alterations and exposure to toxic substances.
As an example of trans-generational effects, exposure to
toxicants during fetal life could be correlated with neuro-
developmental disorders, and epigenetics was considered
to be the probable functional phenotype that communi-
cated these diseases [66].
Occupational exposure to specific industrial processes,
such as the production and use of nanotubes or fuller-
enes, can induce epigenetic alterations directly or indir-
ectly through reactive oxygen species (ROS) [67–69].
Occupational asthma [70] and some metabolic diseases
can modify the epigenetic status and can contribute to
modification of the epigenome. Some neurological dis-
eases, such as Alzheimer’s [71] and Parkinson’s disease
[72], have been linked with occupational exposure to or-
ganophosphates and to alteration of the DNA methylation
landscape in exposed subjects, underlining a possible
cause-effect relationship that needs to be further explored.
Enhancement of genotoxicity and susceptibility markers
Human MN
The MN test is a measure of the increase in micronu-
cleus frequency in cells and is one of the most successful
assays in genetic toxicology because of its ability to
detect both structural and numerical chromosomal
aberrations [73]. It is one of the most widely applied
methods for biomonitoring human populations for
evaluating exposure to genotoxic agents and genetic in-
stability. The test was established in different surrogate
tissues: peripheral blood lymphocytes and erythrocytes,
buccal-exfoliated cells and urine-derived cells (Fig. 5).
However, the CBMN cytome assay in peripheral blood
lymphocytes is the most validated of the methods.
The MN assay, applied in vitro with different estab-
lished cell lines and in human cultured peripheral lym-
phocytes, is recommended as part of the basic battery of
tests to screen new chemical agents for genotoxicity,
allowing the detection of both clastogenic and aneugenic
compounds. Indeed, the OECD has published guidelines
for the testing of chemicals using the in vitro and in vivo
MN assays [74, 75].
Biomonitoring human exposure to genotoxic
agents –- CBMN cytome assay in peripheral blood
lymphocytes
The CBMN assay is a standard biodosimetry method en-
dorsed by the International Atomic Energy Agency and
WHO for measuring exposure to ionizing radiation [76].
The use of the MN test in other exposure scenarios
needs to be considered case by case on the basis of the
mechanisms of action of the genotoxic agents.
The CBMN assay was largely applied in human popu-
lations to evaluate occupational and environmental ex-
posure to genotoxic agents belonging to different
chemical classes, with more than 500 associated papers
available in the scientific literature. The most frequently
investigated groups are hospital personnel, followed by
Fig. 5 Application of MN assay in human biomonitoring (effect monitoring) after environmental and occupational exposures
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workers in the chemical industry and agricultural workers.
The use of the lymphocyte CBMN assay in different expos-
ure scenarios was recently evaluated in the framework of
the International Collaborative Project on Micronucleus
Frequency in Human Populations (Human Micronucleus
project, HUMN) using the systematic review approach [77].
All of the different exposures considered in this review
were associated with increased MN frequencies: the
average value calculated was 2.5-fold over the back-
ground, although the heterogeneity of the available
studies and the relevant differences in the quality of the
studies do not allow clear conclusions to be drawn. The
most pronounced effects, evaluated as increases with re-
spect to the control values, were detected in individuals ex-
posed to metals such as arsenic (6.5-fold), lead (3.8-fold),
and chromium (3.5-fold) [78].
Overall, many of the evaluated studies had limitations in
study design, recruitment strategy to enrol exposed and
control subjects, low statistical power and/or lack of reli-
able exposure data. The subject selection in many cases
did not consider the different tasks in which the workers
were involved, the use of protective devices and the
known confounding factors for exposed-control matching.
Further analyses are needed to elaborate guidelines for the
use of the CBMN assay in biomonitoring studies.
MN assay in buccal-exfoliated cells
The MN) cytome assay in uncultured buccal-exfoliated
epithelial cells is a minimally invasive approach for
evaluating genomic damage and cell death in the human
aero-digestive tract (for more information on MN assay
in buccal-exfoliated cells, see Additional file 1: Info
Box 4) [79–83]. Our recent meta-analysis provides
evidence for the utility of the MN assay using buccal-
exfoliated cells in the pre-screening as well as in the
follow- up of pre-cancerous oral lesions. A significant
excess of MN in patients compared with matched con-
trols was observed for patient subgroups with oral and
neck cancer (meta-mean ratio (MR) of 2.40, 95% CI:
2.02–2.85) or leukoplakia (meta-mean ratio MR 1.88,
95% CI: 1.51–2.35) [84].
The overall objective of the WG 5 project group is to
provide research and training programs covering hazard
characterization, risk identification and various early ef-
fects biomarkers, including carcinogenicity bioassays.
The leader of the WG 5 group are acknowledged expert
in the field and provide valuable support for the interdis-
ciplinary projects where needed.
WG 2 human biological monitoring – More than
(just) analysis of biomarkers
Exposures to chemicals and particles
A generic view that can be applied to most uses of bio-
markers is their contribution to an understanding of the
causal link between environmental exposure(s) and the
onset and morbidity of disease. From the perspective of
epidemiology, the gaps between cause and health out-
come may be bridged by the use of biomarker-based
research (WG 2). In occupational and environmental
health, the use of biomarkers is embedded in a process
termed “human biological monitoring” and defined as
“the standardized and repeated systematic collection,
pretreatment, storage and analysis of body tissues to as-
sess the internal dose of a xenobiotic substance by ana-
lysis of the parent substance and/or a product of
biotransformation” [85]. A much wider definition of bio-
monitoring also includes biomarkers that do not carry
chemical structure information (a “unique signature”)
that enables the researcher to link a biomarker value to
a specific external factor.
Biomonitoring consists of standardized protocols for
the periodic detection of early, preferably reversible, bio-
logical signs that are indicative, when compared with
adequate reference values, of an actual or potential con-
dition of exposure, effect or susceptibility, possibly
resulting in health damage or disease. These signs are
referred to as biomarkers [86]. In 1986, Henderson and
Zielhuis defined the three types of biomarkers as bio-
markers of exposure, of effect, and of susceptibility. Not
all biomarkers can be easily classified in this system but
it is useful to have a discussion as to how a specific bio-
marker can be effectively employed in a study design
(see Additional file 1: Tables S6 and S7). The functional
property of an exposure biomarker is that they carry the
signature of a chemical/environmental contaminant
marker that can be interpreted in the context of an ex-
posure [87]. Effect biomarkers can provide information
on the impact of environmental exposure on molecular,
cellular or tissue levels. This ‘effect’ can be interpreted as
an ‘adverse’ outcome but it often indicates a ‘response’
that can also be interpreted as a beneficial event, pro-
tecting the exposed individual, such as in enzymatic
DNA repair. Thus, the terms “biomarker of response” or
“‘biomarker of early effect” can also be used (see Fig. 6).
A biomarker cannot always be attributed to a specific
causative factor because most of these biomarkers lack
chemical structural information, making them non-
specific for the causative agent. The contextual informa-
tion is important for making inferences about the
possible involvement of one or more environmental ex-
posures and the use of these biomarkers requires study
formats that are particularly well thought-through in
their design (Fig. 6).
Susceptibility biomarkers can be used to identify a per-
son for a specific property that may be the result of
genetic constitution, acquired properties or both. With
these biomarkers, it is possible to classify an individual
as “susceptible”‘or “resistant”‘to an exposure. The term
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“susceptibility”‘is also given a wide interpretation and, at
a group level, it is possible to determine an effect meas-
ure, such as an Odds Ratio, to assess health risk for a
subgroup with one (or more) susceptibility characteris-
tics for comparison with another subgroup with a differ-
ent susceptibility profile. It is not very useful to interpret
a susceptibility outcome for an individual. As for the use
of effect biomarkers, the interpretation of susceptibility
biomarkers relies on a study designed to support inter-
pretation of susceptibility data in a population.
Nowadays, biomarkers are often applied in population-
based studies. Many years of experience have demon-
strated that the laboratory-based analysis of biomarkers is
usually performed well, because of well-established and
rigorous quality assurance. Comparatively, other tasks are
performed less successfully and are often suboptimal, e.g.
sample collection and data interpretation may have weak
spots that contribute to an overall moderate outcome (see
Additional file 1: Table S8). As a consequence, biomoni-
toring studies sometimes do not provide useful results. In
a recent study performed in response to the 9/11 Twin
Towers terrorist attack in New York, the authors con-
cluded that “‘…this study cannot provide any information
about exposure or potential health effects” [88]. One of
the problems was that insufficient consideration was given
to the timing of sample collection relative to the time
point of suspected exposure. Also, the groups that were
selected for comparison of their biomarker levels were not
well suited to the aims of the study.
The availability of a factsheet with the most relevant
characteristics of a chemical substance may support
well-informed decision-making during the preparation
phase. During the EU FP7 project Biomonitoring of
Exposure to Carcinogenic Substances (BIOMONECS), a
format was developed for this purpose, with the
biomonitoring application datasheets (BADS) providing
the most relevant information in a concise format.
For 15 chemical substances, BADS are available on
www.humanbiologicalmonitoring.eu (last updated in
2010). The most recently published BADS are for mercury
and methyl mercury [89]. This structured presentation
may be useful if time is limited for the deployment of bio-
monitoring following a chemical incident.
The WG 2 group also supports the research and train-
ing of toxicology knowledge (including nanotechnology
and particle toxicology, see below) and with knowledge
about the management and risks of chemicals.
Air pollution and particulate matter
Oxidative potential – a possible metric of particle toxicity
Air pollution is a complex mixture of chemically differ-
ent components. Particulate matter (PM) has been des-
ignated as one of the most important components of the
burden of disease from air pollution. How particles elicit
their responses has not been fully elucidated but many
studies have implicated the importance of reactive
oxygen species (ROS) formation and oxidative stress in
particle toxicity. The oxidative potential of a particles –
their ability to generate ROS in cell- free systems – has
been suggested as a promising metric for predicting par-
ticle toxicity. The oxidative potential could provide a
simple screening tool for new nano-materials and a
more relevant dose metric in epidemiological studies.
ROS and oxidative stress in particle-induced toxicity
The role of ROS and oxidative stress in particle toxicol-
ogy has been based, at least partly, on the observation
that particles generate ROS in cell-free systems such as
aqueous buffers, that increased ROS levels are measured
within particle-exposed cells, and that antioxidants
inhibit various cellular responses induced by particles
[90–94]. Figure 7 presents an overview of cellular ROS
production in particle-exposed cells [95] (see also
Additional file 1: Table S9, [90–94, 96–100]). An
overview of the endogenous components involved in cel-
lular redox -regulation is presented in an attachment
(Additional file 1: Table S10).
Beyond oxidative potential – the role of redox signaling in
cellular responses to PM
Oxidative stress and redox responses are considered to
play a central role in particle-induced toxicity. It is often
assumed that the biological reactivity of a particle is be-
cause of its oxidative potential: the ability to produce
ROS or be able to oxidize target substrates directly in
contact with biological fluids or cellular molecules.
Fig. 6 Human biomonitoring: how a specific biomarker can serve as specific aim in a study design. The “meet-in-the-middle” principle to show
how biomarkers can be used prospectively to contribute to human health risk assessment and retrospectively in population-based studies to
identify molecules for suitability as intermediate biomarkers of “‘early effect”effect’ to link exposure biomarkers with disease endpoints
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However, particle exposure may also initiate a number
of endogenous redox responses in cells or tissues. In-
flammatory responses are considered to be contributory
in the development or exacerbation of health effects
from exposure to all types of particulates and they in-
volve multiple levels of ROS-production and redox regu-
lation. Clearly, inflammatory processes lead to oxidative
stress, as activated immune cells produce and release
ROS [96–99]. However, several pro-inflammatory genes
are regulated through autocrine or paracrine signaling
loops initiated by early cytokines such as interleukin
(IL)-1α/β and tumor necrosis factor-α [101, 102]. Both
the transcriptional activation and maturation/release of
these pro-inflammatory mediators, as well as signaling
from their respective receptors, involves multiple redox-
regulated processes that could be affected by antioxidant
treatment [91, 103–105]. The pathological importance of
the oxidative potential of the particles versus these sec-
ondary redox responses of exposed cells may not be easy
to disentangle, and may require much more sophisti-
cated approaches than mere antioxidant treatment. An
in-depth understanding of the role of endogenous redox
regulation in these cellular responses is important,
therefore, in order to clarify the relevance of oxidative
potential as a metric for predicting particle toxicity.
Rapid methods for the detection of disease/exposure
biomarkers, infections, food and environmental
contaminants
Previous sections have described the importance of
detection of both hazardous materials and exposure-
related markers for our understanding of the associated
diseases and their development and for optimization of
early detection and clinical interventions. This cannot be
effectively achieved without high sensitivity, specific and
multi-target analytical platforms that are robust and
easy-to-use, can generate appropriate measurements
very rapidly, and can be applied in non-laboratory set-
tings. This approach will facilitate near-patient testing
and is cognizant of the imperative to develop testing reg-
imens that are accessible, minimally invasive and ameli-
orate the overburdening of health care services. This will
require a variety of approaches and will definitely involve
the integration of the measurement of different targets
including proteins, miRNAs, circulating nucleic acids,
cells, exosomes and many other molecular species. Thus,
Fig. 7 Potential sources of ROS formation in particle- exposed cells. Note: interpreting the effects of antioxidants on cellular responses from particle
exposure is inherently difficult due to the many potential sources of ROS. ROS may be generated directly by reactive particle surfaces in contact with
aqueous media, soluble organic constituents such as PAHs and quinones may form ROS and reactive electrophilic metabolites through redox cycling
and metabolic activation, Fenton-reactive transition metals may contribute to formation of highly reactive hydroxyl radicals (●OH), activation of
intracellular signaling pathways may trigger production of superoxide (O2●-) and hydrogen peroxide (H2O2) through activation of membrane bound
oxidases, and damage to mitochondria may lead to superoxide production. The figure has previously been published in [95]
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what is required is the capability to handle multiple
matrices as sample sources, integration of binders to
monitor specific targets (e.g. antibodies, nucleic acid
probes) and highly sensitive detection strategies.
The focus of this DiMoPEx partner is the development
of rapid diagnostic systems for the detection of a variety
of targets using polyclonal, monoclonal and recombinant
antibodies. The strategies used include electrochemical
and optical detection (surface plasmon resonance, fluor-
escence, chemiluminescence and absorbance) mainly on
microfluidics-based platforms. We generate recombinant
antibody-derived structures highly customized for the
specific application. We also run an international
master’s program in biomedical diagnostics and are very
involved in scientific approaches for antibody isolation,
characterization and subsequent assay development.
In respect of outreach, a DiMoPEx training partner is
the Applied Biochemistry Group, Dublin City University,
which has a unit (AbYBiotech) that develops customized
recombinant antibodies and has all the necessary equip-
ment and developmental pipelines for antibodies and as-
says (see Additional file 1: Table S11). The successful
antibodies need to be fully characterized, with the entire
sequence defined and published or available, and this is
now facilitated through the use of recombinant antibodies.
In relation to DiMoPEx, the group provides opportunities
for collaboration in a number of areas, including antibody
generation, assay use and validation, exchange of re-
searchers for training, development of education and sci-
ence outreach. Examples of the research and the potential
for collaboration within DiMoPEx can be gleaned from
the literature published by the group [106–112].
WG 3: Environmental and occupational
epidemiology overarching other WGs
Epidemiology is the branch of science that deals with
the study of the causes, distribution, and control of dis-
ease in populations. Occupational and environmental
epidemiology deals specifically with the impact of
occupational and environmental exposures on health
and disease in populations. Although experimental and
toxicological methods to establish mechanisms for a cer-
tain exposure and its impact on organisms are available,
most often the only way to confirm the link between an
exposure and the outcome is observational epidemiologic
studies addressing disease occurrence in human popula-
tions. Such population-based studies are the only way to
address the exposure-response relationship and to explore
susceptibility and societal exposures simultaneously.
Radon exposure, for example, affects smokers and
non-smokers equally but, because smokers have a higher
basic risk, the total burden is dominated by lung cancer
in smokers. As an example, the International Agency for
Research on Cancer (IARC) evaluates whether a certain
exposure can cause cancer in humans based on epi-
demiological evidence or a combination of evidence
from epidemiological and animal or mechanistic studies
(www.IARC.fr).
The objectives of the Epidemiology WG (WG3) are to:
 provide a sustainable research and training program
in the field of environmental and occupational
epidemiology for early career investigators;
 In collaboration with other WGs, provide
opportunities for participation in environmental and
occupational epidemiological research, more
specifically in the development of novel
exposure–response relationships, in the area of
exposure-related diseases;
 provide training in the epidemiology of
exposure-related diseases – computer skills
training will focus on epidemiological modelling.
Including spatio-temporal, exposure-response and
interaction modelling.
In DiMoPEx, WG3 provides input and expertise with
regards to study design for the other WGs. In collaboration
with WG1 and WG2 for example, the WG3 contributes
with knowledge about exposure assessment strategies and
how to utilize the available data in the most efficient way
by exploring alternative exposure metrics (for example, in-
dividual measurements versus group-based measurements,
cumulative exposure versus period-specific exposure). The
members of WG3 share experience with the use of large
register-based population studies, in combination with in-
dividual exposure measurements obtained from industry-
based cohort studies, in order to learn about the advantage
of both types of data. WG3 includes researchers with ex-
perience in different kinds of exposure-assessment tools in
individuals, groups or large populations, including bio-
markers, individual- and area- based exposure measures in
the environment, and questionnaires. Figure 2 displays the
major tools for exposure assessment.
We have introduced register data sources from
Denmark – (Danish Occupational Cohort DOC*X
(www.DOC-X.dk) and register resources at Aarhus
University (http://cirrau.au.dk/). Furthermore, in collabor-
ation with other WGs, the WG Epidemiology WG3 group
has submitted a number of spin-off research project pro-
posals, including “Can pyrethroid pesticides cause diabetes?”
and “The effect of organic dust and endotoxin exposure on
CVD, lung cancer and interstitial lung disease”.
WG 4 provides solutions for ethical aspects of
data collection and communication for other
groups
WG 4 supports the research of other groups and pro-
vides training programs for all ethical aspects of data
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collection, communication and publication ethics. Fo-
cusing on early carrier investigators (which are in focus
of COST program actions), the DiMoPEx project aims
to provide knowledge about data privacy regulations.
Ethics framework
An international ethics reference framework for biomed-
ical research involving human subjects already exists and
the researchers can and must be able to refer to this in
their work (see Additional file 1: Table S12). While this
reference framework is international, the legal anchoring
of principles to which this framework refers is provided by
national law. National regulations are mostly based on the
Oviedo Convention and its Additional Protocol on bio-
medical research that emphasize: the necessity of obtain-
ing informed consent, the requirement that a research
project is submitted to an ethics committee for independ-
ent examination of its scientific merit and multidisciplin-
ary review of its ethical acceptability (in each country in
which any research activity is to take place).
Some challenges must be considered carefully: the
authenticity of informed consent, data protection as a
possible obstacle for research, the secondary use of data/
samples, the right of an individual to know or not to know,
and dealing with communication at a collective level.
Informed consent
In general, the authenticity of informed consent can be
questioned for several reasons.:
 The authority or status of the person providing the
information may decisively affect the outcome.
 The accuracy of the information provided can
be limited.
 Correct understanding of the information is a
prerequisite and cannot be assumed if not checked.
 The right to decide is not always synonymous with
the ability to decide for oneself.
 Decisional autonomy can be in conflict with social
constraints.
 The consequences of a decision may be affected by a
perception of power inequality, for instance, when
access to a right can be denied as a consequence of
the outcome.
The process of obtaining informed consent is the
outcome of a complex interaction of personalities.
Awareness and understanding is necessary for correctly
implementing the process. In a pragmatic way, one may
consider consent as authentic when the person is: clearly
free in the decision to participate, is equal in relationship
with the recruiter, is listened to and receives answers at
his or her personal level of understanding, and compre-
hends what s/he consents to.
Communication/right-to-know
The research subjects might have a legally embedded
right to know their individual results from the research,
if they wish. IIndividual results are often not provided to
the study participants because of:
 lack of relevance of the results at an individual level,
 limited time and/or resources,
 fear of causing (unnecessary) alarm,
 scientific uncertainty,
 lack of possible remediation.
Participatory (community engagement) approaches
From an ethical perspective and from a perspective of
increasing confidence and trust in researchers and their
research, it is often not sufficient to leave the decision to
participate in a study to every single individual. The in-
volvement of community members or representatives of
the relevant community in consultation, as a comple-
ment to decision-making autonomy, may also be needed.
This requires the development of methods to include
community consultation, community-based participatory
research, and community consent to research. This can
be done through processes of cooperative inquiry.
Communication
Spreading information about research outcomes is
essential and must occur at the individual as well as at
the collective level. Sufficient information is necessary at
recruitment, during the study, and while disseminating
results (individual and collective, including policy).
There are many challenges for protecting human dig-
nity and the right of the individual research participant,
whilst at the same time not hampering the progress of
research. Practices show a strong belief in scientific
work. Societal acceptance of practices will depend on
good communication at all levels. The future of research
with human subjects will, to a large extent, depend upon
the trust and confidence which is generated in the per-
ception of these (potential) research participants.
Human data sampling and collection: Imminent new OECD
and EU data privacy regulations
The last few years have witnessed an important expan-
sion of human DNA sampling and data collecting in
order to exploit and study the genetic information
collected. The strategic importance of this activity for
genetic research and its applications is obvious, yet many
DNA banks are concerned about how to obtain valid
informed consent and how to deal with retrospective
collections (see Additional file 1: Info Box 5, on new
OECD, Global Science Forum and on EU-The General
Data Protection Regulation, which will become law
across the EU in May 2018).
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WG 6 steps towards NCD diagnosis and
monitoring
Since NCDs not only cause premature deaths and in-
creased morbidity but also have a significant economic
impact, the cost-effective and evidence-based interven-
tions and tools to prevent and control various NCDs
must include:
 reduction of causative exposures/risk factors;
 early detection and management of respective
disorders;
 surveillance of endangered populations to monitor
trends in risk factors and diseases (WG6 in
cooperation with other WGs).
Such interventions are feasible, but they do necessitate
a paradigm shift, away from considering each singular
exposure towards the addressing disease clusters collect-
ively in an integrated manner (“exposome”), moving
away from a purely clinical approach towards a fully in-
tegrated public health approach.
An integrated approach targeting all major common risk
factors, with the aim of reducing premature mortality and
morbidity of chronic NCDs, is clearly the most cost-
effective way to prevent and control the common NCDs.
This requires the integration of primary, secondary, and
tertiary prevention, health promotion and related pro-
grams across numerous sectors and different disciplines.
In order to enhance interdisciplinary cooperation, a clin-
ical network concentrating on exposure-related diseases
will work with DiMoPEx partners in order to 1) develop
common diagnostic scheme guidelines to aid physicians
and public health workers to make best use of the evi-
dence; and 2) integrate NCDs intervention initiatives in
the health system based on primary health care. The inter-
disciplinary team of young European researchers will have
the opportunity to use the analyses within the framework
of the DiMoPEx project to generate risk assessment and
prevention models to improve health and safety in Europe
for the general public, and, more specifically, for workers
and consumers.
Current human studies applying outlined methods on
various exposure scenarios
Exposure to welding fumes and cardiovascular toxicity
DiMoPEx partner, Unit Metals and the Health Unit of
the Institute of Environmental Medicine, Karolinska
Institutet, Sweden, is currently performing research on
health problems in the work environment (welding
fumes and exposure to soot particles) and early-life ex-
posure to metals and health effects during childhood).
The projects are described in brief below:
Exposure to welding fumes increases the risk of CVD
and workplace exposure to welding particles occurs
frequently in Sweden and worldwide. However, we still
do not know what levels of exposure are sufficient to in-
crease the risk of CVD, and whether current welders re-
main at increased risk ot not. In 2010, the group
enrolled welders and controls, all male non-smokers, in
southern Sweden, who were characterized for exposure
to particles and received medical examinations. The au-
thors found that low-to-moderate exposure to welding
fumes can be a risk factor for hypertension [113, 114].
Moreover, the data indicate that welding fumes cause pre-
mature ageing of the cardiovascular system [115], possibly
by increasing oxidative stress [114, 115] from the high
metal content of the welding fumes, as well as epigenetic
changes of the F2RL3 gene, a CVD marker [116].
In contrast, the authors did not find signs of other pre-
viously suggested mechanisms for cardiovascular dam-
age involving exposure to particles [112]. Our group is
now re-examining welders and controls to validate our
cross-sectional findings and quantify the effects of weld-
ing particle exposure on the cardiovascular system, as
well as to explore mechanisms of action, by using a lon-
gitudinal approach. The information about medical and
occupational histories from the welders and controls is
being collected and their heart-rate variability and
endothelial function measured. Further, blood and urine
samples are being collected for measurement of markers
of premature ageing and oxidative stress, as well as
markers of inflammation and one-carbon metabolism
and of coagulation. The approach will address novel
hypotheses, help explain findings from previous studies,
assist in risk assessment, and improve advice to welders
on the safety of working with welding fumes.
Chimney sweeping and risk of cancer
Chimney sweeps in Sweden have an excess risk of bladder,
liver, lung and esophagus cancer. The increase in risk is
likely due to exposure to polycyclic aromatic hydrocar-
bons (PAHs) [117]. It is necessary, therefore, to clarify to
what extent contemporary Swedish chimney sweeps ex-
hibit cancer-related DNA changes and if current levels of
PAH exposure are genotoxic. 1-hydroxypyrene (1-OHP)
has traditionally been used as a proxy for total PAH ex-
posure, although 1-OHPHP is itself not carcinogenic. A
more relevant marker of carcinogenic PAHs, but much
less studied, is 3-hydroxybenzo(a)pyrene (3-OHBaP)
[118]. The aim of the study is to determine early carcino-
genic DNA changes in Swedish chimney sweeps and to in-
vestigate the association between current exposure and
genotoxicity. Chimney sweeps have been recruited for de-
termining exposure, for medical examinations and for the
sampling of biomarkers of DNA damage in blood and
urine. Biomarkers and medical information are also col-
lected in a control set of male warehouse workers with
low exposure to PAHs.
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The study will clarify whether current exposure experi-
enced by chimney sweeps is carcinogenic. If there are
stronger associations for 3-eOHBaP than for 1-OHP
with genotoxicity, this may affect methods used for risk
assessment of PAHs in general, which is important for
the workplace as well as for the general population.
Pesticides exposure and GxE testing in Parkinson’s disease
Parkinson’s disease (PD) is a chronic progressive neuro-
degenerative movement disorder that affects 1% of the
population over the age of 60 years and both genetic and
environmental factors contribute to its etiology. Specific-
ally, occupational pesticide exposures have been identi-
fied as risk factors for PD, but the quality of exposure
assessment varies considerably between studies with
only a few identifying exposure to specific chemicals.;
Some studies recorded ever/never occupational exposure
or self-reports of specific pesticides [119] while others
created job exposure matrixes (JEMs) [120–125], and
only one –- the USA Agricultural Health Study (AHS)
cohort of licensed pesticide applicators –- used a pro-
spective design and collected specific pesticide use in
great detail [126]. Our own California study (known as
the Parkinson’s, Environment and Genes PEG study) re-
cently provided some of the strongest evidence yet that
specific pesticides in combination with genetic suscepti-
bility contribute to the etiology of PD in humans and
that certain pesticides affect pathogenic pathways that
have been related to neurodegeneration. In this
population-based case control study that was conducted
in the heavily agricultural central valley of California,
[127], detailed historical data for active occupational and
household pesticide use was collected and, most import-
antly, we were able to employ a geographic information
system to assess ambient pesticide exposures from
agricultural applications at workplaces and residences.
To generate these exposures to pesticides, we were able
to rely on the state-mandated California Pesticide Use
Reporting (PUR) system (active since 1974), digitized
historical land-use maps and address histories of the
participants [128]. Combining these data sources, we
pinpointed pesticide applications at a precise agricultural
site and related these to the home and work addresses of
the participants to calculate time-specific pesticide expo-
sures based on application rates per acreage or pounds
of pesticide per acre applied annually in the proximity of
their homes or workplaces. Using this unique exposure
assessment tool and the data and bio-samples collected
from almost 1800 study participants, the PEG study pro-
vided the first human evidence that a specific combin-
ation exposure (paraquat and maneb) increased the risk
of PD, confirming animal model findings [129] from toxi-
cological research. We also found that both residential
and workplace exposures contribute to PD risk [130], as
did household use of organophosphate pesticides [131]
and consumption of contaminated well-water [132]. Im-
portantly, we identified gene-environment interactions for
genes in molecular pathways that contribute to PD path-
ology according to animal/ cell studies. The major patho-
physiologic mechanisms we addressed included: 1)
dopamine transporter activity, (DAT); dopamine metabol-
ism pathways (aldehyde dehydrogenase 1 family, member
A1 gene -ALDH1 [133]) relevant to PD; and mitochon-
drial dysfunction due to oxidative/nitrosative stress (nitric
oxide synthase 1 (neuronal) gene – nNOS) [134]. We also
identified genetic susceptibility in the proteasomal path-
ways (SKP1-gene [135]), especially when combined with
exposure to proteasome-inhibiting pesticides (di-thiocar-
bamates): genetic susceptibility related to the response of
the innate immune system among those exposed to pyr-
ethroid pesticides (MHC class II cell surface receptor
encoded by the human leukocyte antigen - HLA-DR)
[136]; DNA repair gene variants (DNA (apurinic or
apyrimidinic site)-lyase gene, 8-Oxoguanine glycosylase 1
(DNA glycosylase) gene, APEX1, OGG1 [136]) that affect
mitochondrial function via oxidative stress; and, finally,
genetic susceptibility to the neurotoxic action of organo-
phosphate pesticides for carriers of variants in the pesti-
cide metabolism gene serum paraoxonase/arylesterase1,
PON1 [137]). A summary of our findings has been pub-
lished recently in the journal Current Environmental
Health Reports [127], in which the importance of integrat-
ing genetic information with advanced exposure assess-
ment methods to describe the combined impact of genes
and environment on biologic pathways relevant to disease
was praised.
Further joint research projects from DiMoPEx part-
ners that focus on the impact of the pollution on human
health are presented in reference [138].
WG 7: Public health protection – how to stimulate
interaction between scientist and policy makers
Collaboration with WHO
In the WHO European Region, diabetes, CVD, cancer,
chronic respiratory diseases and mental disorders cause no
less than 86% of deaths and 77% of the disease burden,
with marked inequalities reflecting a social gradient
(WHO, 2012, see Additional file 1: Info Box 1). The re-
gional strategy and action plan, frame prevention and con-
trol efforts do focus on the proximal risk factors, while
acknowledging the relevance of environmental and
occupational factors (WHO, 2012, see Additional file 1).
DiMoPEx partner(s) aim to collaborate with the WHO, fo-
cusing on environmental determinants of health (with a
spotlight on chemical, fume and dust exposures in living
and working environments). Of mutual interest, is the ana-
lysis of and action on modifiable environmental conditions
or their modifiable components (http://dimopex.eu/ncds/).
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In the context of human health and disease, consideration
of the environment focuses on the aspects that can be
modified through intervention, leading to reduced human
exposure and health impacts, hence offering opportunities
for preventative measures. When assessing the GBD,
WHO analyses modifiable environmental conditions, in-
cluding: pollution of air, water or soil by chemical or bio-
logical agents; occupational risks; ultraviolet and ionizing
radiation; noise; electromagnetic fields; built environments
and housing; land-use patterns; roads; major infrastructural
and engineering works (roads, dams, railways); agricultural
methods; irrigation schemes; man-made vector breeding
places; climate and ecosystem change; environment-related
behavior (WHO, 2016, see Additional file 1).
A resolution on the health impact of air pollution,
adopted at the Sixty-eighth World Health Assembly in
May 2015, and a road map for an enhanced global re-
sponse to air pollution by the health sector provide a
framework to guide actions by Member States, WHO and
stakeholders globally. In the WHO European Region, the
Health 2020 policy, as well as policy commitments from
the Sixth Ministerial Conference on Environment and
Health (Ostrava, June 2017), combine to guide regional ef-
forts designed to reduce environmental burdens on health
and to promote environment-related health benefits
(WHO, 2013; WHO, 2017, see Additional file 1). Occupa-
tional risks contribute to the burden of NCDs (WHO,
2016, see Additional file 1). The burden of disease because
of occupational risk factors, estimated by the GBD project
group, included 304,000 deaths from occupational carcin-
ogens (largely asbestos), 205,000 deaths from occupational
PM, gases and fumes, with 52,000 deaths from occupa-
tional asthmogens (GBD 2013 Risk Factors Collaborators,
2015, see Additional file 1). Important occupational dis-
eases induced by mineral dust and fiber exposure are
pneumoconioses. This group of chronic respiratory dis-
eases, including silicosis, asbestosis and coal-workers’
pneumoconiosis, is estimated to cause 260,000 deaths per
year globally (GBD 2013 Mortality Causes of Death
Collaborators, 2015, in WHO (2016, see Additional file 1).
Since these NCDs are also our focus, the DiMoPEx part-
ners intend to implement the methodological approaches
from WHO and contribute to the process of producing an
estimate of the environmental burden of diseases. The
common approaches include: comparative risk assess-
ment, calculations based on epidemiological data and
expert opinion to fill current gaps in knowledge.
Dissemination and implementation of new knowledge
within a scientific network
The DiMoPEx COST Action is dedicated to catalyze a
joint effort of European scientists to address the issue of
adverse health effects of environmental exposures and to
suggest ways of evaluating and managing them. The
WG 7 is committed to these goals. In this process, facilita-
tion and coordination of information transfer among the
participants, such as between the action core group and
external partners, and effective wide-scale dissemination
and implementation of the new knowledge produced by
the project are essential features.
The first opportunity for networking and for exchange of
knowledge and ideas was the combined meeting of
DiMoPEx WGs in Hamburg in June 2016, when partici-
pants had the opportunity to present their expertise and
backgrounds using posters and thematic oral presentations.
The second working groups meeting was in Bentivoglio,
Italy in October 2017 [138]. In future, specific WG meet-
ings will serve the purpose of formulating concrete plans
for joint projects between the partners and affiliates and
will prepare the ground for formulating new projects. An-
other important tool of internal knowledge dissemination is
the organization of training schools (e.g. on exposure as-
sessment, occupational and environmental epidemiology,
MN methods) and short-term scientific missions of
individual institutional and laboratory visits that provide an
opportunity for building capability in early career investiga-
tors, primarily.
The involvement of external partners in the activities of
the Action, such as the European Society for Environmental
and Occupational Medicine, the Collegium Ramazzini
(http://www.collegiumramazzini.org/about.asp) and the
WHO European Centre for Environment and Health, is
an important priority. In collaboration with WHO and the
International Labour Organization, the DiMoPEx partners
perform a systematic review of the relationship between
pneumoconiosis and occupational dust and fiber expo-
sures, the results of which allow the estimation of the re-
lated burden of disease.
The DiMoPEx website serves as the main platform for
informing participants (http//dimopex.eu), external part-
ners, and the wider-scale scientific and decision-making
community about the research backgrounds of the par-
ticipants, plans for cooperation, events, activities, grant
applications, formulating and ongoing projects, and re-
sults that can be related to the Action.
A further goal of the WG 7 is assembling and critically
assessing information, creating new knowledge, and
implementing this knowledge, by testing and formulat-
ing feasible recommendations for the evaluation and
management of health risks of environmental exposures
and publishing the results in various electronic and
printed media. Apart from the scientific community, the
decision- makers of topic-related sectoral policies and
industries, as well as the general public, are considered
important targets for the dissemination of DiMoPEx re-
sults. The research community is primarily informed
through peer-reviewed scientific publications, research
articles, textbooks and guidelines. At the end of the
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COST-Action, a conference will be organized that will
address not only scientists but also decision- makers and
the general public, with sessions directed to them appro-
priately, and the relevant messages will be disseminated
by an appropriate media coverage.
To ensure the effective and sustainable implementation
of the new knowledge produced, tailored information will
directly be delivered to decision-makers by printed and
electronic leaflets and via the DiMoPEx website.
Summary and conclusions
 Environmental hazardous exposure is among the top
risk factors for chronic disease mortality. A better
understanding of the health-environment (including the
gene-environment) and its interactions in the etiology of
NCDs allows more adequate preventative actions that
could decrease disease morbidity and mortality for many
of the NCDs that are of major public concern.
 Within the COST action DiMoPEx, models will be
developed for the assessment of hazardous
exposures and their potential health consequences
using collected data and available toxicological/
epidemiological evidence.
 DiMoPEx partners believe that combining state-of-
the-art exposure assessment methods with clinical
efforts should grant a more solid basis for both early
recognition and diagnosis strategies, as well as for
the advancement of preventive strategies in Europe.
 The predominant goals of the DiMoPEx project
arinclude helping scientists, physicians and health
officials in preventing and reducing health
impairments associated with various exposure
scenarios and to train highly researchers in these
disciplines with the requisite skills.
 Risk communication expertise developed within the
DiMoPEx action and tools to inform exposed
subjects and the general public are expected to
benefit society.
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